Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody-based oncology therapeutics that target the intersection of angiogenesis, immune response, and tumor growth. The company's pipeline includes four clinical-stage product candidates: Tovecimig, a bispecific antibody targeting DLL4 and VEGF-A for solid tumors; CTX-471, a CD137 agonist for T-cell and NK-cell activation; CTX-8371, a bispecific PD-1/PD-L1 antibody discovered through the company's StitchMabs platform; and CTX-10726, a tetravalent PD-1 × VEGF-A bispecific antibody. The company targets large oncology markets with unmet medical needs, including biliary tract cancer and colorectal cancer, and plans to generate revenue through therapeutic sales following regulatory approval, either by building its own commercial infrastructure or through strategic partnerships. Compass owns worldwide rights to its product candidates (with limited exceptions), maintains its own discovery platform and research infrastructure, holds substantial patent protection extending through the 2030s, and relies on third-party contract manufacturers for supply production.